+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biologics Contract Development & Manufacturing Organization Market - Global Forecast to 2030- Product Image
Biologics Contract Development & Manufacturing Organization Market - Global Forecast to 2030- Product Image
Sale

Biologics Contract Development & Manufacturing Organization Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 182 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011400
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Biologics Contract Development & Manufacturing Organization Market grew from USD 10.59 billion in 2024 to USD 11.40 billion in 2025. It is expected to continue growing at a CAGR of 7.50%, reaching USD 16.36 billion by 2030.

The biologics contract development and manufacturing organization (CDMO) sector has emerged as a vital enabler for the development, scale-up, and commercialization of complex biotherapeutics. Driven by the rapid proliferation of monoclonal antibodies, recombinant proteins, gene therapies, and vaccines, biopharmaceutical innovators are increasingly relying on specialized service partners to navigate intricate production processes, rigorous regulatory pathways, and stringent quality requirements. Within this dynamic ecosystem, CDMOs offer end-to-end solutions spanning cell line development, upstream process optimization, downstream purification, fill-finish operations, and packaging. As the complexity of biologic modalities intensifies, the need for flexible capacity, advanced technology platforms, and agile supply chains becomes paramount.

Outsourcing to CDMOs accelerates time-to-clinical proof-of-concept and supports cost containment by leveraging economies of scale and technical expertise. In parallel, regulatory agencies are raising the bar for process validation, comparability studies, and data integrity, compelling sponsors to partner with organizations that adhere to best-in-class quality systems. This introduction establishes the foundational context for exploring the transformative shifts shaping the CDMO landscape, the implications of emerging trade policies, and the strategic segmentation and regional dynamics that industry leaders must consider to remain competitive.

Transformative Shifts in the Biologics CDMO Landscape

The biologics CDMO landscape is undergoing transformative shifts driven by innovation, digitalization, and changing market dynamics. First, the adoption of single-use bioreactors and modular facilities is enabling rapid deployment of production lines and reducing cross-contamination risk, while continuous manufacturing platforms are enhancing process efficiency and consistency. Second, digital twins, machine learning algorithms, and real-time PAT (process analytical technology) tools are providing unprecedented visibility into critical process parameters, accelerating process development, and enabling predictive quality control.

Regulatory convergence across major markets is harmonizing requirements for comparability and lifecycle management, allowing sponsors to streamline submissions and reduce duplicative studies. At the same time, patient-centric approaches such as personalized cell and gene therapies demand highly specialized small-batch manufacturing capabilities, prompting CDMOs to invest in flexible cleanroom designs and closed-system automation. Finally, strategic partnerships between sponsors, technology providers, and CDMOs are fostering co-innovation models that integrate new modalities, from bispecific antibodies to mRNA platforms, into the development pipeline more seamlessly than ever before.

Cumulative Impact of U.S. Tariffs on Biologics Industry in 2025

In 2025, the United States implemented a series of tariffs affecting key biologics raw materials, analytical reagents, and specialized consumables imported from certain trading partners. These measures have led to a cumulative impact on cost structures, prompting sponsors and CDMOs to reevaluate sourcing strategies. Increased duties on mammalian cell culture media and chromatography resins have driven some organizations to localize production of critical inputs or to secure long-term supply agreements to mitigate price volatility.

Moreover, the tariff framework has incentivized nearshoring of upstream and downstream operations, with several CDMOs expanding domestic capacity to avoid import surcharges and enhance supply chain resilience. Sponsors are also negotiating cost-sharing arrangements and exploring toll-manufacturing agreements to spread the financial burden. The combined effect of these trade measures underscores the importance of agile procurement, diversified supplier networks, and proactive tariff-engineering strategies to maintain competitiveness in a shifting regulatory and economic environment.

Key Market Segmentation Insights

When the market is examined by type, insect platforms leveraging baculovirus expression systems have shown robust scalability for vaccine antigen production, while mammalian systems with advanced cell line development capabilities remain the gold standard for complex glycoproteins. Microbial fermentation technologies continue to provide cost-effective expression for simpler recombinant proteins, and yeast systems optimized for recombinant protein production offer a balance of speed and post-translational modification fidelity.

From a service perspective, cell line development remains a critical first step in biologics manufacturing, followed by downstream process development where analytics and characterization tools converge with tailored purification methods to ensure product quality. Fill-finish operations, including aseptic filling and lyophilization, play a pivotal role in formulation stability and supply chain management, supported by robust packaging solutions and upstream process development efforts that focus on bioreactor scale-up and raw material sourcing.

In terms of application, prophylactic biologics continue to dominate vaccine pipelines, research and diagnostic use relies heavily on protein identification platforms, and therapeutic segments spanning monoclonal antibodies, bispecific antibodies, cell and gene therapies, and vaccines are driving outsized investment in CDMO capacity. Within therapeutic modalities, antibody formats such as antibody fragments and radioimmunoconjugates, gene therapies delivered via viral or non-viral vectors, and recombinant proteins including cytokines, fusion proteins, and hormones each demand specialized manufacturing workflows.

Scale of operation distinctions-preclinical, clinical, and commercial-dictate facility design, batch sizes, and regulatory requirements. End users range from academic and research institutes and government bodies to research laboratories, biopharmaceutical companies, and contract research organizations collaborating on joint development programs. Finally, expression systems categorized as stable or transient expression influence both process timelines and cost structures, underpinning the strategic segmentation of the broader biologics CDMO market.

Key Regional Market Dynamics

In the Americas, a mature biopharmaceutical ecosystem anchored by the United States has driven significant outsourcing volumes to domestic CDMOs, with an emphasis on advanced cell and gene therapy production and strong demand for fill-finish capacity. Canada’s growing biotech clusters have further contributed to regional capacity needs, fostering partnerships between local innovators and global CDMOs.

Europe, the Middle East & Africa have leveraged regulatory harmonization under the European Medicines Agency and the emergence of centers of excellence in the United Kingdom, Germany, and the Nordics. Investment in continuous processing and circular economy initiatives-supported by government incentives-has positioned EMEA as a testbed for sustainability in biologics manufacturing.

In Asia-Pacific, rapid industrialization in China, Korea, and India has spurred the development of greenfield CDMO facilities with single-use technologies and digital control systems. Japan’s established biologics sector continues to invest in high-mix, low-volume capabilities for cutting-edge modalities, while Australia and Southeast Asia are emerging as strategic hubs for clinical trial supply and early-phase manufacturing.

Leading Companies and Strategic Profiles

Leading players in the biologics CDMO arena span a diverse roster of specialized service providers, contract manufacturers, and integrated solutions firms. Industry incumbents such as AbbVie, Inc., Aenova Holding GmbH, Catalent, Inc., Lonza Group AG, and Samsung Biologics have scaled extensive global networks to offer end-to-end development and manufacturing services. Mid-tier and niche providers including Abzena Ltd., Binex Co. Limited, ProBioGen AG, and Rentschler Biopharma SE differentiate through platform-specific expertise in areas like recombinant proteins and gene therapy vectors.

Service integrators and analytical specialists such as Fujifilm Holdings Corporation, Icon PLC, Parexel International Corporation, and Thermo Fisher Scientific, Inc. complement core manufacturing capabilities with contract research, analytical characterization, and regulatory consultation. Emerging entrants like Wrangler Biologics Inc. and strategic equipment partners including JSR Life Sciences, LLC support the ecosystem by providing single-use technologies, bioreactor systems, and specialized consumables that underpin next-generation biologics production.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize investment in digital manufacturing platforms that integrate data analytics, machine learning, and real-time process control to reduce development timelines and improve product consistency. They must also adopt modular facility designs and single-use technologies to enable rapid capacity deployment and flexible production of multiple modalities within the same footprint.

Developing strategic partnerships with raw material suppliers and analytical technology providers can secure preferential access to critical inputs and enable co-development of bespoke solutions that address emerging product needs. Diversifying geographic footprint through nearshore and onshore expansions will mitigate the impact of trade policies and supply chain disruptions while catering to regional regulatory requirements.

Leaders should invest in workforce development and cross-functional training programs to build operational agility and ensure staff competency across both conventional and cell and gene therapy manufacturing platforms. Finally, embedding sustainability metrics-such as energy usage, water consumption, and waste reduction-into every stage of the development and manufacturing lifecycle will enhance corporate responsibility, reduce operational costs, and meet evolving stakeholder expectations.

Conclusion and Strategic Outlook

The biologics CDMO sector stands at a pivotal juncture, shaped by technological breakthroughs, regulatory evolution, and shifting trade policies. Organizations that embrace digitalization, flexible manufacturing paradigms, and strategic geographic diversification will capture outsized growth opportunities and deliver resilient supply chain solutions. As novel modalities such as cell and gene therapies, bispecific antibodies, and mRNA-based vaccines move through development pipelines, the demand for specialized CDMO partners with proven quality systems and innovation roadmaps will intensify.

By aligning service offerings with the unique needs of each modality, and by proactively adapting to tariff landscapes and regional dynamics, CDMOs can secure long-term partnerships with leading biopharma sponsors. Those that invest in sustainable operations, workforce competency, and strategic alliances will not only drive operational excellence but also shape the future of biologics manufacturing.

Market Segmentation & Coverage

This research report categorizes the Biologics Contract Development & Manufacturing Organization Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Insect
    • Baculovirus Expression System
  • Mammalian
    • Cell Line Development
  • Microbial
    • Fermentation Technologies
  • Yeast
    • Recombinant Protein Production
  • Cell Line Development
  • Downstream Process Development
    • Analytics and Characterization
    • Purification Methods
  • Fill-Finish Operations
    • Aseptic Filling
    • Lyophilization
  • Packaging
  • Upstream Process Development
    • Bioreactor Scale-Up
    • Raw Material Sourcing
  • Prophylactic
  • Research and Diagnostic Use
    • Protein Identification
  • Therapeutic
    • Bi-specific Antibodies
    • Cell and Gene Therapies
    • Monoclonal Antibodies
    • Vaccines
  • Antibody Formats
    • Antibody Fragments
    • Monoclonal Antibodies
    • Radioimmunoconjugates
  • Gene Therapies
    • Non-viral Vectors
    • Viral Vectors
  • Recombinant Proteins
    • Cytokines
    • Fusion Proteins
    • Hormones
  • Clinical
  • Commercial
  • Preclinical
  • Academic and Research Institutes
  • Biopharmaceutical Companies
  • Contract Research Organizations
    • Collaborative Research
  • Government Bodies
  • Research Laboratories
  • Stable Expression
  • Transient Expression

This research report categorizes the Biologics Contract Development & Manufacturing Organization Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Biologics Contract Development & Manufacturing Organization Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AbbVie, Inc.
  • Abzena Ltd.
  • Aenova Holding GmbH
  • AGC Biologics GmbH
  • Avid Bioservices, Inc.
  • Binex Co. Limited
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc.
  • Emergent BioSolutions, Inc.
  • Fujifilm Holdings Corporation
  • Icon PLC
  • JSR Life Sciences, LLC
  • Lonza Group AG
  • Parexel International Corporation
  • ProBioGen AG
  • Recipharm AB
  • Rentschler Biopharma SE
  • Samsung Biologics
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific, Inc.
  • Toyobo Co., Ltd.
  • WuXi Biologics Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Biologics Contract Development & Manufacturing Organization Market, by Type
8.1. Introduction
8.2. Insect
8.2.1. Baculovirus Expression System
8.3. Mammalian
8.3.1. Cell Line Development
8.4. Microbial
8.4.1. Fermentation Technologies
8.5. Yeast
8.5.1. Recombinant Protein Production
9. Biologics Contract Development & Manufacturing Organization Market, by Service
9.1. Introduction
9.2. Cell Line Development
9.3. Downstream Process Development
9.3.1. Analytics and Characterization
9.3.2. Purification Methods
9.4. Fill-Finish Operations
9.4.1. Aseptic Filling
9.4.2. Lyophilization
9.5. Packaging
9.6. Upstream Process Development
9.6.1. Bioreactor Scale-Up
9.6.2. Raw Material Sourcing
10. Biologics Contract Development & Manufacturing Organization Market, by Application
10.1. Introduction
10.2. Prophylactic
10.3. Research and Diagnostic Use
10.3.1. Protein Identification
10.4. Therapeutic
10.4.1. Bi-specific Antibodies
10.4.2. Cell and Gene Therapies
10.4.3. Monoclonal Antibodies
10.4.4. Vaccines
11. Biologics Contract Development & Manufacturing Organization Market, by Therapeutics
11.1. Introduction
11.2. Antibody Formats
11.2.1. Antibody Fragments
11.2.2. Monoclonal Antibodies
11.2.3. Radioimmunoconjugates
11.3. Gene Therapies
11.3.1. Non-viral Vectors
11.3.2. Viral Vectors
11.4. Recombinant Proteins
11.4.1. Cytokines
11.4.2. Fusion Proteins
11.4.3. Hormones
12. Biologics Contract Development & Manufacturing Organization Market, by Scale Of Operation
12.1. Introduction
12.2. Clinical
12.3. Commercial
12.4. Preclinical
13. Biologics Contract Development & Manufacturing Organization Market, by End User
13.1. Introduction
13.2. Academic and Research Institutes
13.3. Biopharmaceutical Companies
13.4. Contract Research Organizations
13.4.1. Collaborative Research
13.5. Government Bodies
13.6. Research Laboratories
14. Biologics Contract Development & Manufacturing Organization Market, by Expression System
14.1. Introduction
14.2. Stable Expression
14.3. Transient Expression
15. Americas Biologics Contract Development & Manufacturing Organization Market
15.1. Introduction
15.2. Argentina
15.3. Brazil
15.4. Canada
15.5. Mexico
15.6. United States
16. Asia-Pacific Biologics Contract Development & Manufacturing Organization Market
16.1. Introduction
16.2. Australia
16.3. China
16.4. India
16.5. Indonesia
16.6. Japan
16.7. Malaysia
16.8. Philippines
16.9. Singapore
16.10. South Korea
16.11. Taiwan
16.12. Thailand
16.13. Vietnam
17. Europe, Middle East & Africa Biologics Contract Development & Manufacturing Organization Market
17.1. Introduction
17.2. Denmark
17.3. Egypt
17.4. Finland
17.5. France
17.6. Germany
17.7. Israel
17.8. Italy
17.9. Netherlands
17.10. Nigeria
17.11. Norway
17.12. Poland
17.13. Qatar
17.14. Russia
17.15. Saudi Arabia
17.16. South Africa
17.17. Spain
17.18. Sweden
17.19. Switzerland
17.20. Turkey
17.21. United Arab Emirates
17.22. United Kingdom
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. AbbVie, Inc.
18.3.2. Abzena Ltd.
18.3.3. Aenova Holding GmbH
18.3.4. AGC Biologics GmbH
18.3.5. Avid Bioservices, Inc.
18.3.6. Binex Co. Limited
18.3.7. Boehringer Ingelheim International GmbH
18.3.8. Cambrex Corporation
18.3.9. Catalent, Inc.
18.3.10. Emergent BioSolutions, Inc.
18.3.11. Fujifilm Holdings Corporation
18.3.12. Icon PLC
18.3.13. JSR Life Sciences, LLC
18.3.14. Lonza Group AG
18.3.15. Parexel International Corporation
18.3.16. ProBioGen AG
18.3.17. Recipharm AB
18.3.18. Rentschler Biopharma SE
18.3.19. Samsung Biologics
18.3.20. Takeda Pharmaceutical Company Limited
18.3.21. Thermo Fisher Scientific, Inc.
18.3.22. Toyobo Co., Ltd.
18.3.23. WuXi Biologics Inc.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET MULTI-CURRENCY
FIGURE 2. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET MULTI-LANGUAGE
FIGURE 3. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTICS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF OPERATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF OPERATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2024 VS 2030 (%)
FIGURE 20. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY INSECT, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BACULOVIRUS EXPRESSION SYSTEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY INSECT, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY FERMENTATION TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY YEAST, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY RECOMBINANT PROTEIN PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY YEAST, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM PROCESS DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ANALYTICS AND CHARACTERIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PURIFICATION METHODS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY FILL-FINISH OPERATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ASEPTIC FILLING, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LYOPHILIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY FILL-FINISH OPERATIONS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PACKAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM PROCESS DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOREACTOR SCALE-UP, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY RAW MATERIAL SOURCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY RESEARCH AND DIAGNOSTIC USE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROTEIN IDENTIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY RESEARCH AND DIAGNOSTIC USE, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BI-SPECIFIC ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL AND GENE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ANTIBODY FORMATS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ANTIBODY FRAGMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY RADIOIMMUNOCONJUGATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ANTIBODY FORMATS, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY HORMONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COLLABORATIVE RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GOVERNMENT BODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY STABLE EXPRESSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TRANSIENT EXPRESSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY INSECT, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY YEAST, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY FILL-FINISH OPERATIONS, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY RESEARCH AND DIAGNOSTIC USE, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ANTIBODY FORMATS, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY INSECT, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY YEAST, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY FILL-FINISH OPERATIONS, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY RESEARCH AND DIAGNOSTIC USE, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ANTIBODY FORMATS, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY INSECT, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY YEAST, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY FILL-FINISH OPERATIONS, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY RESEARCH AND DIAGNOSTIC USE, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ANTIBODY FORMATS, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 136. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 137. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY INSECT, 2018-2030 (USD MILLION)
TABLE 138. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 139. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 140. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY YEAST, 2018-2030 (USD MILLION)
TABLE 141. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 142. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 143. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY FILL-FINISH OPERATIONS, 2018-2030 (USD MILLION)
TABLE 144. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 145. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 146. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY RESEARCH AND DIAGNOSTIC USE, 2018-2030 (USD MILLION)
TABLE 147. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 148. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 149. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ANTIBODY FORMATS, 2018-2030 (USD MILLION)
TABLE 150. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 151. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 152. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 153. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 155. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 156. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 157. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY INSECT, 2018-2030 (USD MILLION)
TABLE 158. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 159. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 160. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY YEAST, 2018-2030 (USD MILLION)
TABLE 161. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 162. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 163. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY FILL-FINISH OPERATIONS, 2018-2030 (USD MILLION)
TABLE 164. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 165. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 166. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY RESEARCH AND DIAGNOSTIC USE, 2018-2030 (USD MILLION)
TABLE 167. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 168. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 169. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ANTIBODY FORMATS, 2018-2030 (USD MILLION)
TABLE 170. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 171. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 172. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 173. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 175. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 176. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 177. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY INSECT, 2018-2030 (USD MILLION)
TABLE 178. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 179. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 180. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY YEAST, 2018-2030 (USD MILLION)
TABLE 181. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 182. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 183. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY FILL-FINISH OPERATIONS, 2018-2030 (USD MILLION)
TABLE 184. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 185. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 186. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY RESEARCH AND DIAGNOSTIC USE, 2018-2030 (USD MILLION)
TABLE 187. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 188. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 189. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ANTIBODY FORMATS, 2018-2030 (USD MILLION)
TABLE 190. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 191. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 192. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 193. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 195. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 196. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 197. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 198. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY INSECT, 2018-2030 (USD MILLION)
TABLE 199. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 200. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 201. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY YEAST, 2018-2030 (USD MILLION)
TABLE 202. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 203. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 204. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY FILL-FINISH OPERATIONS, 2018-2030 (USD MILLION)
TABLE 205. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 206. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 207. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY RESEARCH AND DIAGNOSTIC USE, 2018-2030 (USD MILLION)
TABLE 208. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 209. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 210. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ANTIBODY FORMATS, 2018-2030 (USD MILLION)
TABLE 211. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 212. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 213. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 214. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 215. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 216. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 217. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 218. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 219. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY INSECT, 2018-2030 (USD MILLION)
TABLE 220. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 221. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 222. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY YEAST, 2018-2030 (USD MILLION)
TABLE 223. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 224. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 225. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY FILL-FINISH OPERATIONS, 2018-2030 (USD MILLION)
TABLE 226. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 227. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 228. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY RESEARCH AND DIAGNOSTIC USE, 2018-2030 (USD MILLION)
TABLE 229. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 230. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 231. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ANTIBODY FORMATS, 2018-2030 (USD MILLION)
TABLE 232. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 233. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 234. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 235. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 237.

Companies Mentioned

  • AbbVie, Inc.
  • Abzena Ltd.
  • Aenova Holding GmbH
  • AGC Biologics GmbH
  • Avid Bioservices, Inc.
  • Binex Co. Limited
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc.
  • Emergent BioSolutions, Inc.
  • Fujifilm Holdings Corporation
  • Icon PLC
  • JSR Life Sciences, LLC
  • Lonza Group AG
  • Parexel International Corporation
  • ProBioGen AG
  • Recipharm AB
  • Rentschler Biopharma SE
  • Samsung Biologics
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific, Inc.
  • Toyobo Co., Ltd.
  • WuXi Biologics Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Biologics Contract Development Market - Global Forecast to 2030 - Product Image

Biologics Contract Development Market - Global Forecast to 2030

  • Report
  • 183 Pages
  • Global
From
Biologics Contract Manufacturing Market - Global Forecast to 2030 - Product Image

Biologics Contract Manufacturing Market - Global Forecast to 2030

  • Report
  • 197 Pages
  • Global
From
Biologics Contract Manufacturing Market Size, Share & Trends Analysis Report By Product, By Indication, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Biologics Contract Manufacturing Market Size, Share & Trends Analysis Report By Product, By Indication, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 180 Pages
  • Global
From
Biologics Contract Development Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Biologics Contract Development Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Biopharmaceuticals Contract Manufacturing Market Size, Share, & Trend Analysis Report by Source, Service (Process Development), Drug Type (Biologics, Biosimilars), Type, Scale of Operation, Therapeutic Area, Region, and Segment Forecasts, 2025-2030 - Product Image

Biopharmaceuticals Contract Manufacturing Market Size, Share, & Trend Analysis Report by Source, Service (Process Development), Drug Type (Biologics, Biosimilars), Type, Scale of Operation, Therapeutic Area, Region, and Segment Forecasts, 2025-2030

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.